User contributions
Jump to navigation
Jump to search
- 01:26, 2 May 2024 diff hist -14 m Immunotherapy toxicity management current
- 01:26, 2 May 2024 diff hist +15 m Immunotherapy toxicity management →Guidelines
- 01:24, 2 May 2024 diff hist -2,558 m Immunotherapy toxicity management →Guidelines
- 01:04, 2 May 2024 diff hist +108 m Category:Guideline pages current
- 01:04, 2 May 2024 diff hist -8 m NCCN guidelines →Fatigue current
- 01:03, 2 May 2024 diff hist -8 m ESMO guidelines →Palliative care current
- 01:03, 2 May 2024 diff hist +36 N Category:Guideline pages Created page with "Category:General reference pages"
- 01:03, 2 May 2024 diff hist -8 m ASCO guidelines current
- 01:02, 2 May 2024 diff hist +32 m NCCN guidelines
- 01:01, 2 May 2024 diff hist -13 m ESMO guidelines
- 01:00, 2 May 2024 diff hist +2 m ASCO guidelines →Pain
- 01:00, 2 May 2024 diff hist +2 m ASCO guidelines
- 01:00, 2 May 2024 diff hist +28 m ASCO guidelines
- 00:05, 2 May 2024 diff hist +634 m Pyruvate kinase deficiency current
- 20:14, 1 May 2024 diff hist +3 m Ovarian cancer →Carboplatin, Pegylated liposomal doxorubicin, Bevacizumab {{#subobject:a38gbb|Regimen=1}} current
- 15:53, 1 May 2024 diff hist +6 m Nasopharyngeal carcinoma current
- 13:47, 1 May 2024 diff hist -167 m Breast cancer →AC-T {{#subobject:633n67|Regimen=1}} current
- 22:56, 30 April 2024 diff hist +209 m How I Treat →Waldenström macroglobulinemia (WM) current
- 22:54, 30 April 2024 diff hist +751 m Follicular lymphoma →References current
- 19:46, 30 April 2024 diff hist +1,008 m Breast cancer, HER2-positive current
- 17:35, 30 April 2024 diff hist +1,912 Multiple myeloma, relapsed-refractory →VTD {{#subobject:96881b|Regimen=1}} current
- 17:27, 30 April 2024 diff hist +14 m Multiple myeloma, relapsed-refractory →Regimen variant #2 {{#subobject:fc94h1|Variant=1}}
- 13:11, 30 April 2024 diff hist 0 m Soft tissue sarcoma →Doxorubicin monotherapy {{#subobject:826f82|Regimen=1}} current
- 13:07, 30 April 2024 diff hist +1,701 m Soft tissue sarcoma →Doxorubicin monotherapy {{#subobject:826f82|Regimen=1}}
- 12:58, 30 April 2024 diff hist +44 m Soft tissue sarcoma →References
- 11:33, 30 April 2024 diff hist +20 m Soft tissue sarcoma →Cisplatin monotherapy {{#subobject:6e93fa|Regimen=1}}
- 11:31, 30 April 2024 diff hist +19 m Desmoid tumor current
- 11:29, 30 April 2024 diff hist -7 m Desmoid tumor →Nirogacestat monotherapy {{#subobject:f3agdc|Regimen=1}}
- 11:27, 30 April 2024 diff hist +86 m Breast cancer, triple negative current
- 11:05, 30 April 2024 diff hist +2 m Breast cancer, triple negative →References
- 11:04, 30 April 2024 diff hist +25 m Breast cancer, triple negative →Carboplatin & Gemcitabine (GCb) {{#subobject:d46b34|Regimen=1}}
- 11:03, 30 April 2024 diff hist +2 m Breast cancer, triple negative →References
- 11:02, 30 April 2024 diff hist +2 m Breast cancer, triple negative →References
- 11:01, 30 April 2024 diff hist +44 m Breast cancer, triple negative →References
- 11:00, 30 April 2024 diff hist +46 m Breast cancer, triple negative →FEC-D {{#subobject:0cagj9|Regimen=1}}
- 10:58, 30 April 2024 diff hist +5 m Breast cancer, triple negative →Carboplatin & Docetaxel {{#subobject:82336a|Regimen=1}}
- 10:56, 30 April 2024 diff hist +614 m Breast cancer, triple negative →References
- 23:39, 29 April 2024 diff hist +804 m Breast cancer - null regimens →Placebo current
- 23:33, 29 April 2024 diff hist +166 m Tisotumab vedotin (Tivdak) current
- 23:32, 29 April 2024 diff hist +551 m Cervical cancer →Advanced or metastatic disease, subsequent lines of therapy current
- 23:38, 28 April 2024 diff hist +264 m Lutetium Lu 177 dotatate (Lutathera) →History of changes in FDA indication current
- 21:59, 28 April 2024 diff hist +1,125 Low-grade glioma, pediatric →Temozolomide monotherapy {{#subobject:7b66b|Regimen=1}} current
- 21:54, 28 April 2024 diff hist +1,193 N Tovorafenib (Ojemda) Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tovorafenib NCI Drug Dictionary]: An orally available inhibitor of wild-type..." current
- 21:48, 28 April 2024 diff hist +56 m Drug index →T current
- 12:28, 28 April 2024 diff hist +217 m Upper tract urothelial carcinoma current
- 12:27, 28 April 2024 diff hist +1,402 m Upper tract urothelial carcinoma
- 12:25, 28 April 2024 diff hist +521 m Upper tract urothelial carcinoma - null regimens →References current
- 16:49, 27 April 2024 diff hist +213 m Marginal zone lymphoma current
- 16:46, 27 April 2024 diff hist +3 m Marginal zone lymphoma →References
- 15:02, 27 April 2024 diff hist +258 m Marginal zone lymphoma